Thymosin-β4

Healing & repair In trials Human trials

Also called Tβ4, Timbetasin, often sold as TB-500

A 43-amino-acid peptide found in nearly all human cells. It binds actin, the protein cells use to move, which helps repair cells migrate into damaged tissue. Animal studies link it to blood vessel growth, faster wound and corneal healing, and less scarring and inflammation.

Evidence at a glance

Evidence: Human trials — Studied in people
Status: Reached clinical trials
Dosing: A dose has been tested in humans

Dry eye trials showed promise but no approval followed. Sold widely as 'TB-500', often as a different fragment than the full peptide.

What studies report

Faster corneal and skin wound healing in animals and early eye trials
Reduced scarring and inflammation after heart injury in animals
Drives cell migration into damaged tissue

How it works

Regulates actin, the protein cells use to move, which lets repair cells migrate into damaged tissue. Frequently stacked with BPC-157 for severe musculoskeletal injury.

Binds a receptor on the cell surface and signals inward

Where it acts

Joints & cartilage

The library groups this compound under Healing & repair. The diagram shows that target, not every tissue it reaches.

Illustrated

Fine actin filaments in a mammalian cell cytoskeleton.

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Severe musculoskeletal injuryTendon and ligament repairReduced scarringOften stacked with BPC-157Tissue repair and recoveryTendon and muscle injury

Reasons people seek it out — not a list of proven effects.

In practice Unapproved use

Usually run as a loading period followed by less frequent maintenance
The standard partner to BPC-157 for serious soft-tissue injury
Favoured for chronic injuries that have stopped responding to physio
Sold pre-blended with BPC-157 as a “Wolverine stack”, and in wider blends with GHK and thymosin-α1

Science hasn't caught up: Most people buying 'TB-500' receive a fragment rather than the full 43-amino-acid peptide — the names are used interchangeably in the market but are not the same molecule.

Reported real-world use, not evidence and not a recommendation.

Dosing

What was tested Evidence

Topical eye drops, twice daily28 daysDry eye phase 2/3 trials→ Improved signs and symptoms in some endpoints

What people report using Not evidence

2–2.5 mg twice weekly as a loading period, then weekly maintenance
Routinely paired with BPC-157

The injected musculoskeletal use people report has no trial behind it — the human trials were topical, for the eye.

Reported for reference, not as instruction. Nothing here is a recommendation to take anything, and most of these compounds are not approved for human use.

Status: Clinical trials for dry eye and skin wounds. Not approved.

Route: Subcutaneous injection, from reconstituted lyophilised powder; also sold as a ready-made intranasal spray
Sequence: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Formula: C212H350N56O78S
Molecular weight: 4963.4 g/mol
CAS: 77591-33-4
Available as: 10 mg

View on PubChem →

Search PubMed for Thymosin-β4 → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Compared with

vs BPC-157 →

Side-by-side pages for the compounds this one is most often confused with or taken alongside.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.